Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Julphar
Argus Health
Moodys
Merck
Baxter
Colorcon
Cerilliant
Federal Trade Commission

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,585,397

« Back to Dashboard

Summary for Patent: 5,585,397

Title: Sulfonamide inhibitors of aspartyl protease
Abstract:The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Inventor(s): Tung; Roger D. (Arlington, MA), Murcko; Mark A. (Holliston, MA), Bhisetti; Govinda R. (Lexington, MA)
Assignee: Vertex Pharmaceuticals, Incorporated (Cambridge, MA)
Application Number:08/142,327
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,585,397

PCT Information
PCT FiledSeptember 07, 1993PCT Application Number:PCT/US93/08458
PCT Publication Date:March 17, 1994PCT Publication Number: WO94/05639

International Patent Family for Patent: 5,585,397

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary224027► Subscribe
China1061339► Subscribe
China1181755► Subscribe
Colombia4870779► Subscribe
Cyprus2164► Subscribe
Cyprus2317► Subscribe
Czech Republic9500587► Subscribe
Czech Republic289475► Subscribe
Czech Republic9703293► Subscribe
Czech Republic291054► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Novartis
Cipla
Accenture
Farmers Insurance
Daiichi Sankyo
McKesson
Medtronic
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot